Vaxcyte's VAX-31 met or exceeded immune responses versus Pfizer's Prevnar 20 and Merck's Capvaxive across 28 shared strains. Analysts see a clear regulatory path and potential market share capture in a multibillion-dollar adult vaccine market. The stock surged 27% to $71.75; Pfizer and Merck fell.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
